Femasys is trading 6.4% lower at $1.46 amid broader market weakness; no clear company-specific announcement was identified for October 23. - Major indexes moved lower, with the Dow down 1.45%. - Biotech was also lower, while geopolitical tensions and rising oil weighed on markets. - The October 20 SandsRx partnership is prior news and does not establish a direct reason for today’s decline; no trading-volume information was provided.